Associate Professor Sindhu Cherian, MD
Sindhu Cherian, MD is an Associate Professor of Laboratory Medicine at the University of Washington in Seattle. She is board certified in clinical pathology and hematopathology. She received her medical degree from Emory University in Atlanta, GA, followed by a residency and fellowship at the University of Pennsylvania, Philadelphia, PA. Her clinical activities include flow cytometry, morphology, and laboratory hematology. Her research interests are primarily in clinical flow cytometry, with a focus in test development. She is currently serving as vice president of the International Clinical Cytometry Society (ICCS). Dr. Cherian has a strong interest in education and serves on the education committee of ICCS and is on the course committee of the Clinical Cytometry Education Network (CCEN). Dr. Cherian has co-authored a book for the College of American Pathologists (CAP) press titled: “Flow Cytometry in Evaluation of Hematopoietic Neoplasms: A Case-Based Approach.” At the University of Washington, Dr. Cherian serves as an associate program director of the clinical pathology residency program.
Dr Andrew Filby
Dr Andrew Filby graduated summa cum laude from the University of Huddersfield, achieving a 1st class honours in Biochemistry. He spent the third year of his undergraduate degree working for Syngenta in their central toxicology laboratory developing a flow cytometry-based assay for measuring intracellular cytokine production. After graduating, he undertook a PhD at the National Institute for Medical Research (NIMR) in Mill Hill, London. He worked on the Src family kinases LCK and Fyn in adaptive immunity obtaining his PhD in molecular and cellular immunology in association with University College London (UCL). Dr Filby remained in the immunological field, working as a post-doctoral researcher in the laboratory of George Kassiotis, also at the NIMR, working on models of retroviral infection. He then worked for a short time in the commercial sector before taking up the deputy head role of the cytometry core at the London Research Institute (now the Francis Crick). Dr Filby is currently director of the Newcastle University Cytometry and Single Cell Core Technology Unit. He leads a dedicated team of cytometry specialists with the sole aim of developing and implementing comprehensive, cutting edge cytometry methods for the wider research community at Newcastle University and beyond. A significant part of his focus is the development of novel cytometry-based techniques that have underpinned several high profile publications in journals including Science (2012, 2017 and 2018), Cell (2013) and Nature (2018). He also received the Cytometry Part A “paper of the year” accolade in 2011 for his work on debunking the myth of asymmetric division in adaptive immunity. He specialises in Imaging Flow Cytometry with a particular focus on “label-free” characterisation of cell phenotypes and transition states using machine and deep learning approaches. Dr Filby is also an International Society for the Advancement of Cytometry (ISAC) council member for “technology development”. Prior to this, he was one of the first people selected as part of the “Shared Resource Laboratory (SRL) Emerging Leaders” programme. He serves on a number of ISAC committees and task forces and is heavily involved in a several educational initiatives for cytometry at both national and international levels. Dr Filby is driven by a passion to “measure all things of all cells in all biological systems”.
Dr Edwin Hawkins
Dr Edwin Hawkins is an immunologist and cancer biologist. His laboratory uses in vitro and in vivo live cell microscopy to understand development of immune disorders, haematological malignancies and the development of chemotherapy resistance. He conducted his PhD in the Immunology division at WEHI. After being awarded an NHMRC early career fellowship in 2008, Edwin relocated to the Peter MacCallum Cancer Centre where he studied mechanisms that regulate lymphocyte fate and development of leukemia. In 2012, Edwin relocated to Imperial College London with fellowships from the Wellcome Trust and the European Haematology Association to establish 2-photon microscopy techniques that allow long-term tracking of immune cells and leukemia development in vivo. Edwin returned to WEHI October 2015 as an NHMRC RD Wright Fellow to establish his own research program.
Professor Wolfgang Kern, MD
Wolfgang Kern, MD is head of the flow cytometry department at MLL Munich Leukemia Laboratory, Munich, Germany, which is a national and international reference laboratory. He received the medical degree at University of Göttingen and spent residency and fellowship at the University of Munich. He is board-qualified hematologist. At MLL he is focusing on diagnosing hematologic malignancies in a multidisciplinary setting applying flow cytometry in combination with cytomorphology, cytogenetics/FISH and molecular genetics. He is ICCS Council Member and is serving the ICCS Advocacy Committee, the ICCS Quality & Standards Committee and the ICCS Program Committee. Furthermore, he is acting as a reviewer for the German accreditation body and member of its Sectorial Committee on medical laboratories as well as heading various national EQA programs on flow cytometry.
Professor Andy C. Rawstron
Dr Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. He became a Clinical Scientist at the Haematological Malignancy Diagnostic Service (HMDS) in Leeds and completed a PhD on cellular and molecular aspects of multiple myeloma in 2002. He has co-authored more than 130 publications in the field of haematological malignancy diagnosis and monitoring and was a key contributor to the 2016 ‘Clinical Cytometry’ special issue on the flow cytometric detection of MRD in myeloma. Dr Rawstron’s work into the understanding of CLL, both in terms of defining the nature of the precursor condition Monoclonal B-Lymphocytosis and in developing and standardising the assessment of minimal residual disease (MRD) in CLL, has been internationally recognised. His work in coordinating a standard approach to MRD analysis in CLL has encouraged close collaboration between many of the laboratories on the cutting edge of CLL research. Dr Rawstron has a hospital service commitment to develop, select and interpret relevant tests for the diagnosis, treatment and monitoring of haematological malignancy. Within this role he has developed an award-winning service for monitoring people with MGUS, CML and CLL before and after treatment, which provides regular postal monitoring for over 2,000 people.